

## Deutsch

DGAP Ad-hoc-Service

Tel: +49 (0)89 444 430 050 Fax: +49 (0)89 444430-071 Email: [newsroom@eqs.com](mailto:newsroom@eqs.com)

---

Meldende Gesellschaft:  
Aladdin Healthcare Technologies SE

ISIN:  
DE000A12ULL2

Ansprechpartner:  
Aladdin Healthcare Technologies SE  
Wade Smith  
Tel.: 030 700140449  
Fax:

Meldebeauftragter:  
Aladdin Healthcare Technologies SE  
Wade Smith  
Tel.: 030 700140449  
Fax:

E-Mail Ansprechpartner:  
E-Mail Meldebeauftragter:

[info@aladdinid.com](mailto:info@aladdinid.com)  
[info@aladdinid.com](mailto:info@aladdinid.com)

Börsenplätze: Regulierter Markt in Düsseldorf

Systemzeit: 13:00 CET/CEST Veröffentlichungszeitpunkt: 13:30 CET/CEST

---

DGAP-Ad-hoc: Aladdin Healthcare Technologies SE / Schlagwort(e): Rechtssache  
Aladdin Healthcare Technologies SE: Bußgeldankündigung der BaFin in Höhe von insgesamt ca.  
EUR 155.000

15.08.2022 / 13:30 CET/CEST

Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014,  
übermittelt durch DGAP - ein Service der EQS Group AG.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---

Berlin, Deutschland, 15. August 2022 - Aladdin Healthcare Technologies SE ("die Gesellschaft")  
gibt bekannt, dass die Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) die Gesellschaft  
in Kenntnis gesetzt hat, dass sie beabsichtigt, Bußgelder in Höhe von insgesamt ca.  
EUR 155.000 gegen die Gesellschaft zu verhängen.

Gegenstand der Bußgelder sind verspätete und unvollständige Finanz- und  
Halbjahresfinanzberichte der Gesellschaft (Verstöße gegen §§ 114, 115 WpHG). Die  
Gesellschaft hat die Bußgelder im Rahmen einer Verständigung akzeptiert. Der Gesellschaft  
wird nachgelassen werden, die in Aussicht gestellten Bußgelder in 30 Monatsraten zu zahlen.

Kontakt:

Aladdin Healthcare Technologies Holding SE, Unter den Linden 10, 10117 Berlin, Tel 0307700 140  
449, Fax 030/700 140 150, email: [info@aladdinid.com](mailto:info@aladdinid.com), [www.aladdinid.com](http://www.aladdinid.com)

Ende der Insiderinformation

---

15.08.2022 CET/CEST Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,  
Corporate News/Finanznachrichten und Pressemitteilungen.  
Medienarchiv unter <http://www.dgap.de>

---

Sprache: Deutsch  
Unternehmen: Aladdin Healthcare Technologies SE  
Unter den Linden 10  
10117 Berlin  
Deutschland  
Telefon: 030 700140449  
E-Mail: [info@aladdinid.com](mailto:info@aladdinid.com)  
Internet: [www.aladdinid.com](http://www.aladdinid.com)  
ISIN: DE000A12ULL2  
WKN: A12ULL  
Börsen: Regulierter Markt in Düsseldorf  
EQS News ID: 1420467

---

1420467 15.08.2022 CET/CEST

---

Nachricht an BaFin:

Zeitpunkt der Entscheidung über den Aufschub der Veröffentlichung:  
17.09.2021 11:00 CET/CEST

**Aladdin Healthcare Technologies SE**  
with its registered office in Berlin, Germany  
Commercial Register of the Local Court of Charlottenburg under no. HRB 173762 B  
(the “**Company**”)

---

**MINUTES OF A RESOLUTION OF THE ADMINISTRATIVE BOARD  
DATED 17 SEPTEMBER 2021 REGARDING  
THE DELAY OF DISCLOSURE OF INSIDE INFORMATION PURSUANT TO ART. 17 PARA. 4  
MARKET ABUSE REGULATION**

---

The following directors of the Administrative Board (the “**Directors**” and each a “**Director**”) of the Company were present or duly represented at this meeting (the “**Meeting**”) of the Administrative Board of the Company (the “**Board**”):

**Present:**

- Wade Menpes-Smith, Director, Chairman of the Administrative Board, joining by way of conference call;
- Bimal Shah, Director, joining by way of conference call;
- Hamish Badenoch joining by way of conference call.

The Chairman reported that Federal Financial Supervisory Authority (Bafin) had initiated investigations regarding the potential violations of financial reporting obligations with respect to half-year and financial year reporting as notified to the Company by letter dated 2. December 2020. The Company had replied to the letter by its counsel by letter dated 4. February 2021. Bafin then issued a further letter dated 16 September 2021 in which it outlined that it believes the Company had violated the respective provisions and that it intends to resolve its investigations by fines of up to EUR 237,000 including costs. The Company is of the opinion that the proposed fines are too high for various reasons and intends to challenge the reasoning of Bafin. The Board believes that the fines can be reduced substantially.

The Board determined due to the amount mentioned in the letter, that potentially it could qualify as inside information pursuant to Art. 7 MAR as it might have a significant effect on the price of the shares of the Company.

The Board discussed to make use of the possibility outlined in Art. 17 para. 4 MAR and delay the publication of these circumstances by way of an ad-hoc notification. An immediate publication of the content of the letter of Bafin might cause disadvantages to the Company, as the capital markets might deem the amount of fines already final. In addition, there is the high likelihood of a substantial reduction of the fines to a level, which would not be deemed inside information. Also, the underlying facts of the Bafin investigation, i.e. the delay in publication of financial information, are known to the capital markets. Therefore, the Company is of the opinion that an immediate release will jeopardize the interest of the Company and its legal position towards Bafin and that the interest to keep the information confidential until the administrative procedure with Bafin, including a potential settlement, are finally determined or are at least in a stage, where the final outcome is likely. The interest of the Company outweighs the interest of the capital market for immediate information. In particular, the Company might face pressure from the market to accept the conditions mentioned in the Bafin letter despite its position that the violations in questions shall only be subject to a substantially lower fine, if at all. The procedure initiated by Bafin is to the best knowledge of the Company not publicly known at the moment.

**RESOLUTIONS**

After having carefully considered and discussed the above, the Board therefore **UNANIMOUSLY RESOLVES:**

1. It assesses the facts outlined above to potentially qualify as inside information within the meaning of Art. 7 MAR.
2. To delay the disclosure of the potential inside information on the current status of the BaFin procedure in accordance with Art. 17 para. 4 MAR.
3. To examine the present situation continuously and regularly with regard to all new facts occurring and the degree of probability of occurrence and the considerable potential for influencing the share price that may result from such new developments. The Administrative Board will also review the question of the continued existence of the grounds for exemption pursuant to Art. 17 para. 4 MAR, reassess them if necessary and document its decision on an ongoing basis.

The following persons were involved in the adoption of this resolution:

Name	Telephone number	Business address
Wade Menpes-Smith	+44 (0) 7747 075724	Epworth House, 25 City Road, London EC1Y 1AA
Bimal Shah	+44 (0) 7714 719696	Epworth House, 25 City Road, London EC1Y 1AA
Hamish Badenoch	+44 (0) 7900 326568	Epworth House, 25 City Road, London EC1Y 1AA

There being no further items on the agenda and no one present demanding to speak.

London, 17 September 2021

### English

DGAP Ad-hoc-Service

Tel: +49 (0)89 444 430 050 Fax: +49 (0)89 444430-071 Email: newsroom@eqs.com

Issuer:  
Aladdin Healthcare Technologies SE

ISIN:  
DE000A12ULL2

Contact:  
Aladdin Healthcare Technologies SE  
Wade Smith  
Phone: 030 700140449  
Fax:

Agent:  
Aladdin Healthcare Technologies SE  
Wade Smith  
Phone: 030 700140449  
Fax:

E-mail Contact: info@aladdinid.com  
E-mail Agent: info@aladdinid.com

Listings: Regulated Market in Dusseldorf

System Time: 13:00 CET/CEST Release Time: 13:30 CET/CEST

DGAP-Ad-hoc: Aladdin Healthcare Technologies SE / Key word(s): Legal Matter  
Aladdin Healthcare Technologies SE: Notice of fine by BaFin in the total amount of approximately EUR 155,000

15-Aug-2022 / 13:30 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

Berlin, Germany, 15 August 2022 - Aladdin Healthcare Technologies SE ("the Company") announces that the German Federal Financial Supervisory Authority (BaFin) has informed the Company that it intends to impose fines in the total of approximately EUR 155,000 against the Company.

Subject of the fines are late and incomplete financial and half-yearly financial reports of the Company (violations against sections 114, 115 of the German Securities Trading Act "WpHG"). The Company has accepted the fines by way of a settlement. The company will be allowed to pay the fines in 30 monthly installments.

Contact:

Aladdin Healthcare Technologies Holding SE, Unter den Linden 10, 10117 Berlin, Tel 0307700 140 449, Fax 030/700 140 150, email: info@aladdinid.com, www.aladdinid.com

End of Inside Information

---

15-Aug-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at [www.dgap.de](http://www.dgap.de)

---

Language: English  
Company: Aladdin Healthcare Technologies SE  
Unter den Linden 10  
10117 Berlin  
Germany  
Phone: 030 700140449  
E-mail: info@aladdinid.com  
Internet: www.aladdinid.com  
ISIN: DE000A12ULL2  
WKN: A12ULL  
Listed: Regulated Market in Dusseldorf  
EQS News ID: 1420467

End of Announcement

DGAP News Service

---

1420467 15-Aug-2022 CET/CEST

---

Message for BaFin:

Time of the decision to delay the publication of this news:

17-Sep-2021 11:00 CET/CEST

**Aladdin Healthcare Technologies SE**

with its registered office in Berlin, Germany

Commercial Register of the Local Court of Charlottenburg under no. HRB 173762 B  
(the “**Company**”)

---

**MINUTES OF A RESOLUTION OF THE ADMINISTRATIVE BOARD  
DATED 17 SEPTEMBER 2021 REGARDING  
THE DELAY OF DISCLOSURE OF INSIDE INFORMATION PURSUANT TO ART. 17 PARA. 4  
MARKET ABUSE REGULATION**

---

The following directors of the Administrative Board (the “**Directors**” and each a “**Director**”) of the Company were present or duly represented at this meeting (the “**Meeting**”) of the Administrative Board of the Company (the “**Board**”):

**Present:**

- Wade Menpes-Smith, Director, Chairman of the Administrative Board, joining by way of conference call;
- Bimal Shah, Director, joining by way of conference call;
- Hamish Badenoch joining by way of conference call.

The Chairman reported that Federal Financial Supervisory Authority (Bafin) had initiated investigations regarding the potential violations of financial reporting obligations with respect to half-year and financial year reporting as notified to the Company by letter dated 2. December 2020. The Company had replied to the letter by its counsel by letter dated 4. February 2021. Bafin then issued a further letter dated 16 September 2021 in which it outlined that it believes the Company had violated the respective provisions and that it intends to resolve its investigations by fines of up to EUR 237,000 including costs. The Company is of the opinion that the proposed fines are too high for various reasons and intends to challenge the reasoning of Bafin. The Board believes that the fines can be reduced substantially.

The Board determined due to the amount mentioned in the letter, that potentially it could qualify as inside information pursuant to Art. 7 MAR as it might have a significant effect on the price of the shares of the Company.

The Board discussed to make use of the possibility outlined in Art. 17 para. 4 MAR and delay the publication of these circumstances by way of an ad-hoc notification. An immediate publication of the content of the letter of Bafin might cause disadvantages to the Company, as the capital markets might deem the amount of fines already final. In addition, there is the high likelihood of a substantial reduction of the fines to a level, which would not be deemed inside information. Also, the underlying facts of the Bafin investigation, i.e. the delay in publication of financial information, are known to the capital markets. Therefore, the Company is of the opinion that an immediate release will jeopardize the interest of the Company and its legal position towards Bafin and that the interest to keep the information confidential until the administrative procedure with Bafin, including a potential settlement, are finally determined or are at least in a stage, where the final outcome is likely. The interest of the Company outweighs the interest of the capital market for immediate information. In particular, the Company might face pressure from the market to accept the conditions mentioned in the Bafin letter despite its position that the violations in questions shall only be subject to a substantially lower fine, if at all. The procedure initiated by Bafin is to the best knowledge of the Company not publicly known at the moment.

### **RESOLUTIONS**

After having carefully considered and discussed the above, the Board therefore **UNANIMOUSLY RESOLVES:**

1. It assesses the facts outlined above to potentially qualify as inside information within the meaning of Art. 7 MAR.
2. To delay the disclosure of the potential inside information on the current status of the bafin procedure in accordance with Art. 17 para. 4 MAR.
3. To examine the present situation continuously and regularly with regard to all new facts occurring and the degree of probability of occurrence and the considerable potential for influencing the share price that may result from such new developments. The Administrative Board will also review the question of the continued existence of the grounds for exemption pursuant to Art. 17 para. 4 MAR, reassess them if necessary and document its decision on an ongoing basis.

The following persons were involved in the adoption of this resolution:

<b>Name</b>	<b>Telephone number</b>	<b>Business address</b>
Wade Menpes-Smith	+44 (0) 7747 075724	Epworth House, 25 City Road, London EC1Y 1AA
Bimal Shah	+44 (0) 7714 719696	Epworth House, 25 City Road, London EC1Y 1AA
Hamish Badenoch	+44 (0) 7900 326568	Epworth House, 25 City Road, London EC1Y 1AA

There being no further items on the agenda and no one present demanding to speak.

London, 17 September 2021